On Nov. 9, 2022, Cliff Goodman, PhD, moderated the AMCP Summit on value-based arrangements. He provides his key takeaways from the virtual event in the latest guest blog.
By Cliff Goodman, PhD, AMCP Summit Moderator, The Lewin Group • 1/4/23
AMCP applauds Congress for passing the Pre-approval Information Exchange (PIE) Act of 2022. This bipartisan bill will enhance proactive information-sharing on new treatments between drug manufacturers and health plans.
December 2022 Legislative & Regulatory Briefing: The PIE Act Makes Waves in Washington D.C.; Member Benefit! Read the Latest Regulatory NewsBREAKs; AMCP CEO Susan A. Cantrell Applauds Reintroduction of the PIE Act; AMCP Joins Pharmacy Organizations in Request for Medicaid Guidance to States; AMCP's Adam Colborn Featured in Politico Pro.
On Dec. 15, AMCP joined 29 other pharmacy organizations in a letter calling on the Centers for Medicare and Medicaid Services to build upon the Public Readiness and Emergency Preparedness Act with guidance clarifying that states should reimburse clinical services provided by pharmacists at the same rates as other non-physician providers.
The Health Disparities Advisory Group is focused on developing resources related to data and formulary and utilization management solutions that can close the gap on disparities in medication use. This advisory group is active from March 2022-February 2023.
The Digital Therapeutics Advisory Group is focused on developing resources for payers on when they should evaluate products, what manufacturers should communicate, and understanding how Digital Therapeutics are included in drug compendia. This advisory group is active from March 2022-February 2023.
The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group launched in Q4 2022.